FDA warning letters, untitled letters, import alerts, recalls and consent decrees: what each action means and what came before it.
FDA Warning Letters October 2026
Atlas
All 18 drug and device CGMP and QSR warning letters FDA posted in October 2026, with letter numbers, issue and posting dates, the 21 CFR sections cited, the five recipients already on Import Alert 66-40, and the Form 483 record Atlas holds for each inspected facility.
Import Alert 66-40 in 2026
Atlas
What FDA Import Alert 66-40 is and how a foreign drug facility lands on it, with the two October 2026 warning letters that followed a 66-40 listing: Rohto Pharmaceutical (for its Rohto-Mentholatum facility in Vietnam, inspected in April 2026) and TSP Solutions in Singapore (reviewed through a 704(a)(4) records request). Includes an Atlas count of the 472 Red List entries by country as of the October 27, 2026 version, a comparison of import alerts and warning letters, and the steps FDA expects before removing a firm.
FDA Compounding Warning Letters 2026
Atlas
What FDA's September 2026 warning letters to Empower Pharmacy (Houston, 503A) and SCA Pharmaceuticals (Little Rock, 503B) cite, how 503A pharmacies and 503B outsourcing facilities differ on CGMP and on compounding copies of approved drugs, when semaglutide and tirzepatide left the shortage list, and what 52 Form 483s issued at registered outsourcing facilities in 2025 and 2026 cite most.
FDA Untitled Letters Explained
Atlas
An FDA untitled letter is an advisory letter for violations that do not meet the threshold for a warning letter. This guide covers how the Regulatory Procedures Manual separates the two, which FDA offices send untitled letters, the 15 working day response OPDP asks for, how many OPDP letters FDA has posted each year since 2017, and how an untitled letter compares with a Form 483, a warning letter and a regulatory meeting.
Chlorthalidone 25 mg tablets made by Inventia Healthcare in India and distributed by Rising Pharma were recalled twice in 2026, in June and September, for failed dissolution specifications. This piece covers the lots, what a dissolution failure means, the manufacturer's FDA inspection and Form 483 history, and what quality teams should check.
FDA Import Alerts Explained.
Atlas
FDA Import Alerts can trigger detention without physical examination and freeze revenue at the border. This guide explains how the framework works, which root causes drive alerts, and the upstream quality and documentation practices manufacturers need to stay off the red list.
GLP-1 Imports Under Scrutiny.
Atlas
The FDA issued an import alert targeting GLP-1 ingredients to stop counterfeit and substandard raw materials. This post covers what the alert does, how it affects global suppliers, and what quality teams need to change to keep market access.
Warning Letters and Market Risk.
Atlas
FDA warning letters create real risks for pharma investors: production disruption, import alerts, recalls, legal costs, and delayed approvals. This post breaks down how regulators escalate, what the market reacts to, and the checklist to run before investing.
FDA posts its warning letters in a searchable table on fda.gov. This guide shows how to search it by company, issuing office, subject and date, how to read closeout and response letters, what a warning letter contains, and how to connect any letter to the inspection and Form 483 that came before it, with four facility histories as worked examples.
FDA Consent Decrees Explained.
Atlas
An FDA consent decree is a court order, usually a permanent injunction, that a company agrees to after the Department of Justice sues on FDA's behalf. This guide explains how a firm reaches one, what the decree requires, how long it lasts and how it ends, lists well-known FDA consent decrees from 2012 to 2024, and shows the inspection record behind three of them.
FDA Violations and Warning Letters.
Atlas
An FDA warning letter is the agency's formal notice that it found significant violations and expects them corrected. This guide covers where the letter sits on FDA's escalation ladder, what it contains, the regulations most often cited on the Form 483s that precede one (drugs and devices, from the Atlas directory), the 2026 Fresenius and Olympus letters, and how to respond inside 15 business days.
How Warning Letters Affect Inspections.
Atlas
FDA warning letters are public notices of regulatory non-compliance. They freeze new drug approvals, invite follow-up inspections, and damage reputation. This post covers the consequences and the CAPA-driven response that reduces long-term impact.